

May 04, 2017

Version 1

CAP inhibition in hymenoptera venom allergy V.1

 [PLOS One](#)

DOI

<https://dx.doi.org/10.17504/protocols.io.ht7b6rn>

Savi Eleonora¹, Peveri Silvia¹, Montagni Marcello¹

¹UOsD Allergologia, Ospedale G.da Saliceto - Piacenza Italy



Silvia Peveri

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.ht7b6rn>

External link: <https://doi.org/10.1371/journal.pone.0180270>

Protocol Citation: Savi Eleonora, Peveri Silvia, Montagni Marcello 2017. CAP inhibition in hymenoptera venom allergy. protocols.io <https://dx.doi.org/10.17504/protocols.io.ht7b6rn>

Manuscript citation:

Savi E, Incorvaia C, Boni E, Mauro M, Peveri S, Pravettoni V, Quercia O, Reccardini F, Montagni M, Pessina L, Ridolo E (2017) Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study. PLoS ONE 12(7): e0180270. doi: [10.1371/journal.pone.0180270](https://doi.org/10.1371/journal.pone.0180270)

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Created: May 04, 2017

Last Modified: March 28, 2018

Protocol Integer ID: 5727

Keywords: cap inhibition in hymenoptera venom allergy, hymenoptera venom allergy, cap inhibition

Attachments



[IO 7 RAST INIBIZIONE...](#)

220KB

- 1 **Annual validation:** 17/01/2017
- 2 **BACKGRUOND** A common issue in diagnosis of Hymenoptera venom allergy (HVA) is the occurrence of multiple positive results to the different venoms, mainly due to cross-reactivity between phospholipase A1 for vespids, and hyaluronidase, that may concern all venoms; another important cross-reactivity source is common cross-reactive carbohydrate determinants (CCD)
- 3 **AIM** Provide the laboratory technician with the instructions for the in vitro test
- 4 **FIGURES INVOLVED** laboratory technician and allergologist
- 5 **ACTIVITY DESCRIPTION**
 - Eligible patients: CAP-inhibition is mandatory in the correct choice of the venom to be used for VIT in patients with apparent poly-sensitization
 - Blood sample: Blood sample is collected in a dry tube with a Separator Gel. No fasting is required before exam.
- 6 **EXECUTION**

Two 100 mcl aliquots of patient's serum were incubated separately overnight at 4 °C with 200 mcl of two venoms at increasing dilutions (0; 25 mcg; 50 mcg; 100 mcg 200 mcg/ml). Subsequently slgE against each of the venoms were determined in the samples prepared as above using ImmunoCap technique. The CAP-inhibition test was carried out with a specific programme in UniCap 250 (Thermofisher) with a calibration curve between 0.1 to 100 ku/l slgE concentrations that allows a good evaluation of low values. The extent of homologous (blockage of venom-slge by the same venom) and heterologous (blockage of the venom-slge by the other venom) inhibition was computed with the following formula: % inhibition = $100 - \frac{[\text{IgE inhibited sample (kU/l)} \times 100 / \text{IgE anti-venom (kU/l) at zero concentration of venom}]}{100}$. A percentage of homologous inhibition >70 % was required to perform heterologous inhibition. The same percentage was considered suggestive of cross-reactivity among venoms. The venom preparations tested were the same used for skin tests
- 7 **COMPLICATIONS** Having a small quantity of blood sample can cause problems in running the test that can not be conducted until the end.
- 8 **RECOMMENDATIONS** Take a test tube full enough of blood. It's recommended to use a IgE specific serum concentration below 25-28 ku/l to have a good rate between slge



concentration and venom concentration. Higher values are adjusted with a suitable serum dilution.